# Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials

## TL;DR

This study finds that triple combination therapy is more effective than dual therapy in lowering blood pressure and improving lipid profiles in patients with hypertension and dyslipidemia.

## Contribution

The study introduces and evaluates a novel triple therapy combining ARBs, amlodipine, and rosuvastatin for managing hypertension and dyslipidemia.

## Key findings

- Triple therapy significantly reduced systolic and diastolic blood pressure compared to dual therapy.
- Triple therapy improved LDL cholesterol levels more effectively than ARB/amlodipine combinations.
- No significant differences were observed in adverse events between treatment groups.

## Abstract

Hypertension (HTN) and dyslipidemia are major risk factors for cardiovascular diseases. Recently, researchers have investigated the potential benefits of combining multiple medications in one bill to improve their metabolic and cardiovascular efficacy.

We investigated a treatment approach that combines two antihypertensive medications with one statin. We aim to assess the safety and effectiveness of a triple therapy regimen consisting of angiotensin receptor blockers (ARBs) combined with amlodipine/rosuvastatin. We compared this triple therapy to dual therapy involving either ARBs/amlodipine or ARBs/rosuvastatin in patients with HTN and dyslipidemia.

We conducted systematic search in the following databases: Medline, Web of Science, Scopus, and Cochrane Library until August 2024. The main outcomes assessed were the variations in mean systolic blood pressure (mSBP), mean diastolic blood pressure (mDBP), and the percentage changes in LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) following an eight-week treatment period.

Our analysis included seven randomized controlled trials (RCTs) which enrolled 1074 patients. Triple therapy revealed a significant reduction in mSBP (mean difference (MD): -4.06, 95% C.I. [-7.97: -0.15], p-value = 0.04), mDBP (MD: -5.45, 95% C.I. [-7.96: -2.93], p-value = < 0.0001), and LDL-C (MD: -50.10, 95% C.I. [-55.55: -44.64], p-value = < 0.001) compared to ARBs/amlodipine. Triple therapy significantly decreased mSBP (MD: −12.28, 95% C.I. [− 16.68: −7.88], p-value = < 0.001) and mDBP levels (MD: −6.48, 95% C.I. [-10.95: -2.01], p-value = 0.005) compared with ARBs plus rosuvastatin. There was no significant difference in secondary outcomes, including total adverse events, cerebrovascular adverse events, and adverse drug reactions.

Triple therapy has greater effectiveness in decreasing blood pressure in hypertensive patients with dyslipidemia compared to treatments involving ARBs combined with amlodipine or ARBs with rosuvastatin. Additionally, Triple therapy significantly improved lipid profiles compared to the ARB/amlodipine group. Our study lays the groundwork for developing a single-pill, triple-combination therapy. Further RCTs are necessary to confirm our findings.

The online version contains supplementary material available at 10.1186/s43044-026-00720-z.